Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors

1983 ◽  
Vol 13 (4) ◽  
pp. 735-749 ◽  
Author(s):  
E. Marley ◽  
Krystyna M. Wozniak
Keyword(s):  
Amine Oxidase ◽  
Mao Inhibitors ◽  
Clinical Value ◽  
Uptake Inhibitors ◽  
Mao A ◽  
Selective Mao Inhibitors

SynopsisDangerous and even fatal interactions can occur in man following combinations of antidepressants which include non-selective MAO inhibitors. To ascertain the causation, interactions reproducing the clinical phenomena have been elicited in animals with these combinations, and the mechanisms involved have been explored by various pharmacological strategies; 5-HT re-uptake inhibitors proved especially hazardous in combination. Interactions could, however, be avoided even with the 5-HT re-uptake inhibitors, by combination with relatively selective MAO A or B inhibitors, an approach with potential clinical value.

scholarly journals Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase Kinetic Analysis in Mesenteric Arteries of Patients With Type 2 Diabetes

2011 ◽  
pp. 309-315 ◽  
Author(s):  
S. F. NUNES ◽  
I. V. FIGUEIREDO ◽  
J. S. PEREIRA ◽  
E. T. DE LEMOS ◽  
F. REIS ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Monoamine Oxidase ◽  
Kinetic Parameters ◽  
Amine Oxidase ◽  
Mesenteric Arteries ◽  
Patient Age ◽  
Mao B ◽  
Mao A ◽  
Type 2 Diabetic

Monoamine oxidase (MAO, type A and B) and semicarbazide-sensitive amine oxidase (SSAO) metabolize biogenic amines, however, the impact of these enzymes in arteries from patients with type 2 diabetes remains poorly understood. We investigated the kinetic parameters of the enzymes to establish putative correlations with noradrenaline (NA) content and patient age in human mesenteric arteries from type 2 diabetic patients. The kinetic parameters were evaluated by radiochemical assay and NA content by high-performance liquid chromatography (HPLC). The activity of MAO-A and SSAO in type 2 diabetic vascular tissues was significantly lower compared to the activity obtained in non-diabetic tissues. In the correlation between MAO-A (Km) and NA content, we found a positive correlation for both the diabetic and non-diabetic group, but no correlation was established for patient age. In both groups, MAO-B (Vmax) showed a negative correlation with age. The results show that MAO-A and SSAO activities and NA content of type 2 diabetic tissues are lower compared to the non-diabetic tissues, while MAO-B activity remained unchanged. These remarks suggest that MAO-A and SSAO may play an important role in vascular tissue as well as in the vascular pathophysiology of type 2 diabetes.

SELECTIVE MAO INHIBITORS AND REGULATION OF CORTICOSTERONE

Abstracts ◽  
1978 ◽  
pp. 369
Author(s):  
A. Ventura ◽  
S. Parvez ◽  
H. Parvez
Keyword(s):  
Mao Inhibitors ◽  
Selective Mao Inhibitors

Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man

1981 ◽  
pp. 307-316 ◽  
Author(s):  
D. L. Murphy ◽  
D. Pickar ◽  
D. Jimerson ◽  
R. M. Cohen ◽  
N. A. Garrick ◽  
...  
Keyword(s):  
Mao Inhibitors ◽  
Biochemical Indices ◽  
Selective Mao Inhibitors

Effects of combined treatment with clorgyline and selegiline on extracellular noradrenaline and serotonin levels

2012 ◽  
Vol 24 (6) ◽  
pp. 369-373
Author(s):  
Yuji Kitaichi ◽  
Takeshi Inoue ◽  
Shin Nakagawa ◽  
Shuken Boku ◽  
Tsukasa Koyama
Keyword(s):  
Prefrontal Cortex ◽  
Antidepressant Treatment ◽  
Combined Treatment ◽  
Mao Inhibitors ◽  
Mao B ◽  
Promising Strategy ◽  
Mao A ◽  
Antidepressant Action ◽  
Noradrenaline Levels

Kitaichi Y, Inoue T, Nakagawa S, Boku S, Koyama T. Effects of combined treatment with clorgyline and selegiline on extracellular noradrenaline and serotonin levels.Objective Combined treatment with clorgyline, an irreversible monoamine oxidase (MAO)-A inhibitor, and selegiline, an irreversible MAO-B inhibitor, reportedly increases extracellular serotonin levels in the raphe nuclei more than clorgyline does alone. However, the effects of combination of these MAO inhibitors on extracellular noradrenaline have not been reported.Methods Using in vivo microdialysis, we measured extracellular noradrenaline and serotonin levels after administration of clorgyline and/or selegiline in the medial prefrontal cortex of rats.Results Administration of clorgyline (10 mg/kg) significantly increased both extracellular serotonin and noradrenaline levels. Combined treatment using clorgyline (10 mg/kg) and selegiline (3 mg/kg) increased extracellular serotonin and noradrenaline levels more than each drug alone did.Conclusions These findings of this study suggest the augmented antidepressant action of the combination of MAO-A inhibition and MAO-B inhibition. The addition of a MAO-A inhibitor to selegiline or increasing dose of selegiline to achieve full MAO-A inhibition might be the promising strategy for the antidepressant treatment in partial responders or non-responders to selegiline.

More on MAO inhibitors and food

1964 ◽  
Vol 2 (22) ◽  
pp. 88-88
Keyword(s):  
Blood Pressure ◽  
Monoamine Oxidase ◽  
Experimental Work ◽  
Amine Oxidase ◽  
Hypertensive Crisis ◽  
Mao Inhibitors ◽  
Ecg Changes ◽  
Treatment Of Depression ◽  
Oxidase Inhibition ◽  
Inhibition Analysis

We have previously drawn attention to the hypertensive attacks provoked by food substances in patients taking monoamine oxidase inhibitors for the treatment of depression or hypertension (Drug & Therap. Bull. 1963, 1, 44; 1964, 2, 28). Experimental work on patients in America1 has confirmed that tyramine is potentiated up to a hundredfold when given orally or parenterally after a period of amine oxidase inhibition. Analysis of various cheeses1, 2 revealed that cheddar contained more tyramine than well matured varieties such as Camembert and was capable of producing hypertensive crisis in amounts as small as 20 G, thus confirming the earlier clinical reports.3 ECG changes have been reported during attacks and so have large rises in blood pressure of up to 120 mm Hg which may be entirely asymptomatic.4, 7

Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs

2020 ◽  
Vol 20 (18) ◽  
pp. 1593-1600 ◽  
Author(s):  
Riccardo Concu ◽  
Michael González-Durruthy ◽  
Maria Natália D.S. Cordeiro
Keyword(s):  
Side Effects ◽  
Monoamine Oxidase ◽  
Statistical Tests ◽  
Qsar Model ◽  
Monoamine Oxidase A ◽  
Mao Inhibitors ◽  
Computational Approaches ◽  
Linear Discriminant ◽  
Mao B ◽  
Mao A

Introduction: Monoamine oxidase inhibitors (MAOIs) are compounds largely used in the treatment of Parkinson’s disease (PD), Alzheimer’s disease and other neuropsychiatric disorders since they are closely related to the MAO enzymes activity. The two isoforms of the MAO enzymes, MAO-A and MAO-B, are responsible for the degradation of monoamine neurotransmitters and due to this, relevant efforts have been devoted to finding new compounds with more selectivity and less side effects. One of the most used approaches is based on the use of computational approaches since they are time and money-saving and may allow us to find a more relevant structure-activity relationship. Objectives: In this manuscript, we will review the most relevant computational approaches aimed at the prediction and development of new MAO inhibitors. Subsequently, we will also introduce a new multitask model aimed at predicting MAO-A and MAO-B inhibitors. Methods: The QSAR multi-task model herein developed was based on the use of the linear discriminant analysis. This model was developed gathering 5,759 compounds from the public dataset Chembl. The molecular descriptors used was calculated using the Dragon software. Classical statistical tests were performed to check the validity and robustness of the model. Results: The herein proposed model is able to correctly classify all the 5,759 compounds. All the statistical performed tests indicated that this model is robust and reproducible. Conclusion: MAOIs are compounds of large interest since they are largely used in the treatment of very serious illness. These inhibitors may lose efficacy and produce severe side effects. Due to this, the development of selective MAO-A or MAO-B inhibitors is crucial for the treatment of these diseases and their effects. The herein proposed multi-target QSAR model may be a relevant tool in the development of new and more selective MAO inhibitors.

Sign in / Sign up

Export Citation Format

Share Document